Not yet recruiting
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
NCT07812181
- Conditions
- Abnormalities, Multiple, Chromosome Disorders, Congenital Abnormalities, +10 more
- Locations
-
- Children's Hospital Los Angeles Los Angeles, California, United States